Lubiprostone News and Research

RSS

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

Sucampo Pharmaceuticals, Inc. today confirmed that its partner, R-Tech Ueno, Ltd. reported the results of its recently completed phase 2 clinical trial of UF-021 in retinitis pigmentosa patients. The results showed improvement in visual function dose-dependently in both visual field test and subjective findings.

5 Jun 2010

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

Sucampo Pharmaceuticals, Inc. today announced the presentation of results from a phase 3 clinical trial investigating the use of lubiprostone in non-cancer pain patients with Opioid-induced Bowel Dysfunction (OBD). These results were the subject of an oral presentation at the Digestive Disease Week (DDW) 2010 conference in New Orleans, Louisiana, on May 5, 2010.

11 May 2010

Sucampo reports $0.3M net loss, $14.8M total revenue for first-quarter 2010

Sucampo Pharmaceuticals, Inc. today reported its consolidated financial results for the quarter ended March 31, 2010.

11 May 2010

Sucampo Pharmaceuticals presents Phase 2 cobiprostone clinical trial data at DDW 2010

Sucampo Pharmaceuticals, Inc. today presented results of a phase 2 clinical trial of cobiprostone, an investigational drug, for the prevention of gastric ulcers and other gastrointestinal injuries in patients treated with non-steroidal anti-inflammatory drugs (NSAIDs). These data were presented at the Digestive Disease Week (DDW) 2010 conference in New Orleans, Louisiana, as part of the distinguished abstract plenary session.

4 May 2010

Researchers find better way to prep patients for colonoscopy procedures

Researchers at Henry Ford Hospital may have found a better way to prep patients for colonoscopy procedures so they no longer need to drink a gallon of prescribed fluids prior to the procedure.

3 May 2010

Additional data on lubiprostone presented at the GASTRO 2009 UEGF/WCOG meeting

Sucampo Pharma Europe, Ltd., and Sucampo Pharma Americas, Inc., subsidiaries of Sucampo Pharmaceuticals, Inc., today presented additional clinical data for lubiprostone (Amitiza®) at GASTRO 2009 UEGF/WCOG, the joint meeting of the United European Gastroenterology Federation (UEGF), the World Gastroenterology Organisation (WGO), the World Organisation of Digestive Endoscopy (OMED) and the British Society of Gastroenterology (BSG), in London.

25 Nov 2009

Swissmedic grants marketing authorization for Amitiza

Sucampo Pharma Europe Ltd., a subsidiary of Sucampo Pharmaceuticals, Inc., today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted a marketing authorization for Amitiza® (lubiprostone) 24 microgram (mcg) gel capsules for the long-term treatment of patients with chronic idiopathic constipation (CIC).

20 Nov 2009

European MAA for lubiprostone withdrawn by Sucampo Pharma Europe

Sucampo Pharma Europe, Ltd., a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), today announced the withdrawal of its European marketing authorization application (MAA) for lubiprostone, 24 mcg, for the indication of Chronic Idiopathic Constipation (CIC).

5 Sep 2009

Sucampo Pharmaceuticals initiates phase 3 trial of Lubiprostone for chronic idiopathic constipation in Japan

Sucampo Pharmaceuticals, Inc. today announced that its subsidiary, Sucampo Pharma, Ltd., has initiated enrollment and completed the randomization of the first patient into the pivotal phase 3 efficacy trial of lubiprostone for chronic idiopathic constipation (CIC) in Japan.

20 May 2009

Updated guidelines for irritable bowel syndrome

Although irritable bowel syndrome (IBS) is the most common disease diagnosed by gastroenterologists, it's also one of the most misunderstood.

18 Dec 2008

Lubiprostone brings relief for many IBS patients who experience constipation

Many patients may soon find relief from the bloating, cramping, abdominal pain and constipation associated with irritable bowel syndrome, or IBS.

19 May 2008

FDA approves Amitiza for irritable bowel syndrome with constipation

The U.S. Food and Drug Administration today approved Amitiza (lubiprostone) for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adult women aged 18 and over.

29 Apr 2008

FDA accepts Sucampo's sNDA for Lubiprostone for the treatment of irritable bowel syndrome

Sucampo Pharmaceuticals, Inc., has announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA).

18 Sep 2007

NDA for Lubiprostone to treat irritable bowel syndrome with constipation

Sucampo Pharmaceuticals, Inc., has announced that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to seek market approval of a lower strength of lubiprostone (8 mcg) to treat irritable bowel syndrome with constipation (IBS-C).

13 Jul 2007

Lubiprostone News and Research

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

Sucampo reports $0.3M net loss, $14.8M total revenue for first-quarter 2010

Sucampo Pharmaceuticals presents Phase 2 cobiprostone clinical trial data at DDW 2010

Researchers find better way to prep patients for colonoscopy procedures

Additional data on lubiprostone presented at the GASTRO 2009 UEGF/WCOG meeting

Swissmedic grants marketing authorization for Amitiza

European MAA for lubiprostone withdrawn by Sucampo Pharma Europe

Sucampo Pharmaceuticals initiates phase 3 trial of Lubiprostone for chronic idiopathic constipation in Japan

Updated guidelines for irritable bowel syndrome

Lubiprostone brings relief for many IBS patients who experience constipation

FDA approves Amitiza for irritable bowel syndrome with constipation

FDA accepts Sucampo's sNDA for Lubiprostone for the treatment of irritable bowel syndrome

NDA for Lubiprostone to treat irritable bowel syndrome with constipation

Lubiprostone may improve symptom relief rates in adults with irritable bowel syndrome with constipation

Lubiprostone may improve symptom relief rates in adults with irritable bowel syndrome

Cognitive behavioral therapy effective in treating irritable bowel syndrome

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News